R&D Why the government’s latest funding push is critical to the ... Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.